WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory actions
Abrir esta carpeta y ver su contenidoDrug surveillance
Cerrar esta carpetaNew developments
Ver el documentoAbacavir: approved for HIV-1 infection: USA
Ver el documentoAcetylsalicylic acid: approved for use in cardiovascular and cerebrovascular conditions: USA
Ver el documentoCelecoxib: approved for treatment of rheumatoid arthritis and osteoarthritis: USA
Ver el documentoCilostazol: approved for treatment of stable intermittent claudication: USA
Ver el documentoInterferon alfa-2b and ribavirin combination therapy: indications extended: previously untreated hepatitis C patients: USA
Ver el documentoNew formulations
Ver el documentoNewly approved products
Ver el documentoMedical devices
Ver el documentoCFC-free aerosol inhalers (MDIs): update: Malaysia
Ver el documentoLaser for blood tests: approved for home use in diabetic patients: USA
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoMedication errors
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Laser for blood tests: approved for home use in diabetic patients: USA

United States of America. The Food and Drug Administration has approved a new device that offers people with diabetes a means of drawing blood without using traditional lancets. The device: the Cell Robotics’ Lasette: is a portable battery-operated Erbium: YAG laser that can be used in the home after patients have received a prescription and requisite instruction from their health care provider.

Patients with diabetes have to draw blood samples for blood/glucose level analysis once or twice a day. Traditionally, they have had to prick their fingers with lancets to get these samples, a process that can be particularly difficult for children. Lasette uses laser energy to penetrate the skin and is effective for both adults and children with diabetes. As with any laser device, the Lasette requires proper maintenance and instruction in order to be used safely and effectively. Patients will receive this training and instruction material from the prescribing health care provider.

Reference: HHS News P98-38 dated 7 December 1998.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013